- Fee assured
- Verified account
- Video and telephone consultations
Dr. Haidry is a Consultant Gastroenterologist and interventional endoscopist at University College Hospital, London. He trained at St Mary's Hospital in London and completed his Specialist Gastroenterology training in North East London. He was then appointed to a two-year academic fellowship at UCL where he examined state of the art and innovative diagnostic and therapeutic endoscopic techniques for the diagnosis and treatment of early cancers arising in the gastrointestinal tract.
He was appointed as a consultant at UCLH in 2011. He is the Clinical lead for endoscopy at Cleveland Clinic London. His main interests are pre-malignant and malignant disorders of the upper gastrointestinal tract, with a particular interest in Barrett’s and Squamous neoplasia, oesophageal cancer and advanced interventional endoscopy. His main areas of interest and clinical research focus on novel and innovative endoscopic imaging techniques and therapeutic endoscopic approaches such as endoscopic resection, radiofrequency ablation, cryoablation, endoscopic ultrasound and complex stricture management. More recently he has started to work on metabolic endoscopy and was the first person in the UK to perform endoscopic duodenal mucosal resurfacing for Type 2 diabetes patients.
He has an academic position at UCL exploring existing and novel endoscopic imaging technologies for detecting early cancers. His other main research focus is minimally invasive techniques for treating cancers of the upper gastrointestinal tract and metabolic endoscopy. He is active academically and continues to lead and be involved in several national and international clinical trials in these fields. He is a member of the BSG (British Society of Gastroenterology) endoscopy committee and coordinates several highly acclaimed live endoscopy workshops at UCLH every year. He continues to publish extensively and has co-authored several key guidelines over the past 5 years.
Areas of interest
- Expert diagnosis of Heartburn, indigestion and acid reflux
- Wireless BRAVO pH monitoring
- Endoscopic treatment with trans oral incision less fundoplication for GORD
- Diagnosis and surveillance of Barrett’s Oeosphagus early squamous cell cancer of the oesophagus
- Treatment of Barrett’s Oeosphagus with radiofrequency ablation, cryo-ablation and endoscopic resection
- Treatment of patients with complex oesophageal strictures and Achalasia
- Palliation of symptoms with endoscopic therapy for patients with Oesophageal cancer with stents and laser therapy.
- Endoscopic treatment of patent’s with Zenker’s diverticulum
- Gastrointestinal fistula repair with endoscopic suturing.
- Endoscopic sleeve Gastroplasty
- Diagnosis of Small bowel bacterial overgrowth and the use of probiotic therapy, dietary and antibiotic therapy for improvement of symptoms
- Diarrhoea & Constipation
- Abdominal bloating and excessive gas
- Coeliac disease and Food intolerances
- Cleveland clinic london appointments
- 40 Grosvenor Place London SW1X 7AW
- 020 3423 7500
- Debra Hyams
- Cleveland Clinic Consulting Rooms 24 Portland Place London W1B 1LU
- 020 3423 7056
Anaesthetists worked with
- Dr Jason Wilson Not Fee Assured
(Additional) Languages spoken
- French - Basic
Role of body composition and metabolic profile in Barrett's oesophagus and progression to cancer.
Di Caro S, Cheung WH, Fini L, Keane MG, Theis B, Haidry R et al.,Eur J Gastroenterol Hepatol. 2015 Dec 14.
Esophageal neoplasia arising from subsquamous buried glands after an apparently successful photodynamic therapy or radiofrequency ablation for Barrett's associated neoplasia.
Kohoutova D, Haidry R et al.
Scand J Gastroenterol. 2015 Nov
Long-term durability of radiofrequency ablation for Barrett's-related neoplasia.
Haidry R, Lovat L., Curr Opin Gastroenterol. 2015 Jul;31(4):316-20.
Comparing outcome of radiofrequency ablation in Barrett's with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry. Haidry RJ et al. Endoscopy. 2015 Jun 30.
Radiofrequency Ablation for Barrett's Dysplasia: Past, Present and the Future?
Haidry R, Lovat L, Sharma P., Curr Gastroenterol Rep. 2015 Mar;17(3)
Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry, Haidry et al., Gut doi:10.1136/gutjnl-2014-308501
Primary malignant melanoma of the esophagus.
Wallis G, Sehgal V, Haider A, Bridgewater J, Novelli M, Dawas K, Haidry R. Endoscopy. 2015;47 Suppl 1
Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study.
Ross-Innes CS, Debiram-Beecham I, O'Donovan M, Walker E, Varghese S, Lao-Sirieix P, Lovat L, Griffin M, Ragunath K, Haidry R, et al, Fitzgerald RC; BEST2 Study Group.
PLoS Med. 2015 Jan 29;12(1)
Clonal Selection and Persistence in Dysplastic Barrett's Esophagus and Intramucosal Cancers After Failed Radiofrequency Ablation., Zeki SS, Haidry R,et al.Am J Gastroenterol. 2013 Aug 13. doi: 10.1038/ajg.2013.238
Radiofrequency Ablation For Esophageal Squamous High Grade Dysplasia And Early Squamous Cell Carcinoma: Outcomes From The United Kingdom Halo Radiofrequency Ablation National Registry, Haidry Rehan et al.
World Journal of gastroenterology, World J Gastroenterol 2013, 19 volume 36 issue
Radiofrequency Ablation and Endoscopic Mucosal Resection for Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma: Outcomes of the UK National Halo RFA Registry , Rehan J. Haidry, et al.,Gastroenterology 2013;145:87–95
- BSc (Hons) St Mary's Hospital 1998
- MBBS St Mary's Hospital 2001
- FRCP RCP 2005
- MD UCL 2015
Reference number 6028603
- Cleveland Clinic
- 12:00 - 20:00
- 020 3423 7056
- Cleveland Clinic London
- 08:00 - 12:00
- 020 3423 7056
Post treatment communication
Following treatment of a Bupa member, we will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
0203 423 7056